Virpax Pharmaceuticals, Inc.
VRPXDelisted Jul 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708331
Virpax Pharmaceuticals, Inc. was delisted on Jul 21, 2025; its insiders filed their last Form 4 on Jul 10, 2024; 7 institutions reported holding it in 13F filings for Q1 2025, worth $34.9K in total; no superinvestor held it.
13F holders, Q4 2021
Institutional positions in Virpax Pharmaceuticals, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +5 vs. Q3 2021
- Shares held
- 2.24M
- −148.8K (−6.2%) vs. Q3 2021
- Total value
- $7.67M
- −$3.78M (−33.0%) vs. Q3 2021
- New holders
- 9
- 4 more added
- Sold out
- 4
- 4 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRPX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $2 |
| Q1 2025 | 7 | $34.9K |
| Q4 2024 | 12 | $46.7K |
| Q3 2024 | 9 | $66.8K |
| Q2 2024 | 8 | $12.6K |
| Q1 2024 | 6 | $6.44K |
| Q4 2023 | 18 | $120.5K |
| Q3 2023 | 13 | $493.4K |
| Q2 2023 | 14 | $827.7K |
| Q1 2023 | 17 | $873.8K |
| Q4 2022 | 21 | $973.0K |
| Q3 2022 | 16 | $2.17M |
| Q2 2022 | 16 | $3.13M |
| Q1 2022 | 16 | $3.29M |
| Q4 2021 | 18 | $7.67M |
| Q3 2021 | 13 | $11.4M |
| Q2 2021 | 7 | $1.12M |
| Q1 2021 | 5 | $1.29M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Virpax Pharmaceuticals, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 52 | $0 | 0.00% | −500−90.6% | Reduced |
| Advisor Group Holdings, Inc. | 50 | $0 | 0.00% | −38−43.2% | Reduced |
| BlackRock Inc. | 464 | $2.00K | 0.00% | +464 | New |
| Tower Research Capital LLC (TRC) | 643 | $2.00K | 0.00% | +643 | New |
| Morgan Stanley | 4,892 | $16.0K | 0.00% | +2,667+119.9% | Added |
| XTX Topco Ltd | 10,537 | $36.0K | 0.02% | +10,537 | New |
| UBS Group AG | 11,385 | $39.0K | 0.00% | +11,385 | New |
| Engineers Gate Manager LP | 11,790 | $40.0K | 0.00% | +11,790 | New |
| Virtu Financial LLC | 15,279 | $52.0K | 0.01% | +1,568+11.4% | Added |
| Northern Trust Corp | 15,221 | $52.0K | 0.00% | +15,221 | New |
| Cambridge Investment Research Advisors, Inc. | 17,770 | $61.0K | 0.00% | −1,650−8.5% | Reduced |
| Quantum Private Wealth, LLC | 22,500 | $77.0K | 0.03% | +22,500 | New |
| The PNC Financial Services Group, Inc. | 25,125 | $86.0K | 0.00% | +25,125 | New |
| Geode Capital Management, LLC | 47,671 | $163.0K | 0.00% | +37,626+374.6% | Added |
| Citadel Advisors LLC | 98,046 | $336.0K | 0.00% | +98,046 | New |
| Vanguard Group Inc | 327,305 | $1.12M | 0.00% | +48,285+17.3% | Added |
| Kepos Capital LP | 750,000 | $2.57M | 0.21% | 00.0% | Unchanged |
| Sabby Management, LLC | 876,834 | $3.01M | 0.75% | −116,166−11.7% | Reduced |
| Altium Capital Management LP | 0 | $0 | 0.00% | −271,846−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −25,715−100.0% | Sold out |
| National Asset Management, Inc. | 0 | $0 | 0.00% | −18,600−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −100−100.0% | Sold out |